Glucose Trnsporter and PEDF in Psoriasis
Nøgleord
Abstrakt
Datoer
Sidst bekræftet: | 04/30/2020 |
Først indsendt: | 01/20/2020 |
Anslået tilmelding indsendt: | 01/23/2020 |
Først indsendt: | 01/26/2020 |
Sidste opdatering indsendt: | 05/06/2020 |
Sidste opdatering indsendt: | 05/07/2020 |
Faktisk startdato for undersøgelsen: | 07/30/2020 |
Anslået primær afslutningsdato: | 07/30/2020 |
Anslået afslutningsdato for undersøgelsen: | 02/28/2021 |
Tilstand eller sygdom
Intervention / behandling
Diagnostic Test: GLUT 1 gene expression
Fase
Armgrupper
Arm | Intervention / behandling |
---|---|
patients with psoriasis vulgaris only | |
patients with psoriasis vulgaris and type 2 diabetes mellitus | |
healthy control |
Kriterier for støtteberettigelse
Køn, der er berettiget til undersøgelse | Male |
Prøveudtagningsmetode | Non-Probability Sample |
Accepterer sunde frivillige | Ja |
Kriterier | Inclusion Criteria: - Patients with psoriasis vulgaris Patients with psoriasis vulgaris and type 2 diabetes Exclusion Criteria: - Factors affect GLUT 1 expression As: tumors either benign or malignant cause increase GLUT 1 expression |
Resultat
Primære resultatforanstaltninger
1. GLUT1 expression in psoriatic patients with or without type 2 diabetes. [through study completion, an average of 2 year]
2. GLUT1 expression in keratinocyte before and after treatment with pigment epithelium derived factor (PEDF) [through study completion, an average of 2 year]